Skip to main content

Bevacizumab Doubles Risk of GI Adverse Events in Key Ovarian Cancer Trial

Primary tabs

View
Get Stamp Tags
Published Locations

Breadcrumb

Home
Bevacizumab Doubles Risk of GI Adverse Events in Key Ovarian Cancer Trial

User login

Username

Password

Reset your password

Type	Lead	score